Mundipharma ’s Mundesine receives approval from Japan’s MHLW to treat PTCL
Mundipharma has secured regulatory approval of Mundesine (Forodesine hydrochloride) from Japan ’s Ministry of Health, Labour and Welfare (MHLW) to treat relapsed / refractory Peripheral T-Cell Lymphoma (PTCL).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Lymphoma | T-cell Lymphoma